Kiromic BioPharma, Inc.
KRBPQ
$0.00
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.93M | 2.61M | 2.33M | 2.28M | 2.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.71M | 6.60M | 6.35M | 5.11M | 5.32M |
| Operating Income | -5.71M | -6.60M | -6.35M | -5.11M | -5.32M |
| Income Before Tax | -6.49M | -7.44M | -6.83M | -6.15M | -4.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.49M | -7.44M | -6.83M | -6.15M | -4.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.49M | -7.44M | -6.83M | -6.15M | -4.69M |
| EBIT | -5.71M | -6.60M | -6.35M | -5.11M | -5.32M |
| EBITDA | -5.14M | -6.05M | -5.80M | -4.56M | -4.76M |
| EPS Basic | 13.13 | -6.12 | -5.54 | -5.46 | 3.17 |
| Normalized Basic EPS | -2.63 | -3.01 | -2.83 | -2.95 | -2.31 |
| EPS Diluted | 13.13 | -6.12 | -5.54 | -5.46 | 3.17 |
| Normalized Diluted EPS | -2.63 | -3.01 | -2.83 | -2.95 | -2.31 |
| Average Basic Shares Outstanding | 1.55M | 1.55M | 1.51M | 1.30M | 1.27M |
| Average Diluted Shares Outstanding | 1.55M | 1.55M | 1.51M | 1.30M | 1.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |